Business
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Together, the companies will focus on the generation of novel small molecule inhibitors against specified deubiquitinase (DUB) targets, specifically for the treatment of neurodegenerative and other diseases.
Recent reports revealed that the infection rates between adults and children were similar, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
The study was run by Johns Hopkins University and Geisinger Health, testing more than 10,000 women with no previous history of cancer.
Expectations that a vaccine against COVID-19 will be available within a year’s time are mixed, based on recent surveys conducted by BioSpace, as well as the analytics company GlobalData.
Writing in The Motley Fool, Billy Duberstein, the portfolio manager at Stone Oak Capital, pointed at these two treatment options as potential weapons against the pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.
Saniona appoints Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announced that it has appointed Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development starting on May 1, 2020.
Here is a cross-section of some of the surveys about the COVID-19 pandemic over the last few weeks.